View Press Releases

Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings

August 26, 2014

Scientists from AstraZeneca, Chugai Pharmaceutical, Sanford-Burnham Medical Research Institute, and UT Southwestern Medical Center will be among Genedata customers discussing innovations in high content imaging, high throughput screening, compound combination screening, and other related topics.

BASEL, SWITZERLAND - Aug 26, 2014 -  

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the Genedata® Screener Global User Group Meetings will be held in Asia, Europe, and North America during September 2014. Screening experts from global pharmaceutical companies and leading research organizations will gather for annual User Group Meetings to share best practices, case studies, and upcoming challenges in all areas of screening. This year’s sessions will also showcase enhancements and new functionality in the recently released Genedata Screener version 12, which includes data analysis capabilities for Surface Plasmon Resonance (SPR), Thermal Shift, as well as Combination and Panel Screens.

Most of the world’s leading pharmaceutical companies, academic institutions, and contract research organizations rely on Genedata Screener as their single computational platform for all plate-based screening. Genedata Screener users from AstraZeneca, Chugai Pharmaceuticals, Sanford-Burnham Institute, and University of Texas Southwestern Medical Center will be among the speakers presenting their research work using Genedata Screener. Featured sessions will explore topics such as:

  • application of high content imaging and stem cells within phenotypic drug discovery;
  • identification of  novel natural products and synthetic molecules for treatment of lung cancer; and
  • best practices for applying Genedata Screener in a variety of screening environments.

 

“Screener User Group Meetings bring together many of the world’s thought leaders in the application of screening technologies in pharmaceutical R&D,” said Dr. Othmar Pfannes, CEO of Genedata.  “We are proud to host these annual events, which provide forums in which scientists can share their experiences in advancing scientific progress with Genedata Screener -- the most comprehensive computational platform for screening worldwide.”

Genedata Screener User Group Meetings are held regionally throughout the world so that customers can easily access and participate in these knowledge-sharing events. Meetings for 2014 will be held in: Tokyo, Japan (Sept. 4); Basel, Switzerland (Sept. 9-10); Boston, MA (Sept.16); and San Francisco, CA (Sept. 18).

Inquiries may be sent to: ugm@genedata.com.

About Genedata

Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. www.genedata.com. Follow us on LinkedIn.

Media Contact:

Jackie Thrasivoulos

Genedata Screener

Public Relations

Phone: +1 508 380 6408

jackie.thrasivoulos@genedata.com

 

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.